Home » Newsletters » The Carlat Psychiatry Report

The Carlat Psychiatry Report

Antipsychotic Roundup 2007 (March) | 2007

View Archived Issues

Invega: Can You Say "Patent Extender?"

March 1, 2007

Janssen’s marketing team apparently missed the fact that the word in the English language that sounds most like “Invega” is “inveigle,” meaning “to entice, lure, or ensnare by flattery or artful talk or inducements” (www.dictionary.com). You may have already heard some “artful talk” from your Janssen reps, who are keen to have you convert your patients from Risperdal to Invega. Read More

Do Second-Generation Antipsychotics Treat Depression? An Update

March 1, 2007

In this article, guest author Dr. Shalom Feinberg, takes a hard look at the most recent data on the effectiveness of SGAs for depression in its various guises, including treatment-resistant depression (TRD) and bipolar depression (BD). Read More

Choosing the Right Antipsychotic

March 1, 2007

Dr. Carpenter, as Editor-in-Chief of Schizophrenia Bulletin and a long-time researcher in the field, I’m sure you’ve seen trends come and go. Lately, we’ve been hearing a lot about how the older, conventional antipsychotics may be just as good as the newer atypicals. What’s your take? Read More

College students love to abuse Adderall

March 1, 2007

Adderall has overtaken Ritalin as the most-abused stimulant among college students. In a survey, 4,580 college students were asked about their illicit use of drugs. Read More

Bad News for Transcranial Magnetic Stimulation

March 1, 2007

An FDA advisory panel has recommended that TMS not be approved for the treatment of major depression. Neuronetics, the maker of the NeuroStar device (www.neuronetics.com), submitted data from three studies, but only one was a placebo-controlled double-blind trial (Study 101). Read More

Seroquel vs. Depakote for Impulsivity and Aggression in Teens

March 1, 2007

We often see teenagers with co-occurring bipolar disorder and aggressive/impulsive behaviors. While Depakote is often effective, we also often prescribe atypical antipsychotics. A new post-hoc analysis provides some
evidence to bolster that practice. Read More

Omega-3 Fatty Acids for Suicidal Behavior

March 1, 2007

Omega-3 fatty acids have been studied in a number of psychiatric disorders, including autism, bipolar disorder, depression, and schizophrenia. A new study shows a possible benefit for patients with a history of self-harm. Read More

Metformin for Antipsychotic-Induced Weight Gain in Adolescents

March 1, 2007

Atypical antipsychotics can cause significant weight gain in adolescents. In this study, 39 kids between 10 and 18 years of age were randomized to receive either the antidiabetic drug Glucophage (metformin) or a matched placebo; each was added to their primary antipsychotic medication (Risperdal, Seroquel, or Zyprexa) for 16 weeks. Read More